Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 4/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 3/20 | 0.41 |
| ▸ | HTR6 | P50406 | 4/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5359648 | 0.90 | ADORA1 (0.51) | ADORA1ADORA3ADORA2AJAK2MAPK8 | |
| SCHEMBL5363112 | 0.88 | MAPK9 (0.47) | ADORA1ADORA3ADORA2AJAK2MAPK8 | |
| SCHEMBL5356081 | 0.78 | OPRM1 (0.42) | ADORA1ADORA3ADORA2AOPRM1 | |
| SCHEMBL5349697 | 0.76 | HRH4 (0.38) | ADORA1HTR6KCNH2OPRM1OPRK1 | |
| SCHEMBL5357419 | 0.76 | ADORA1 (0.44) | ADORA1ADORA3 | |
| SCHEMBL5357503 | 0.75 | ADORA1 (0.54) | ADORA1 | |
| SCHEMBL5362701 | 0.74 | ADORA1 (0.75) | ADORA1ADORA3MAPK8 | |
| SCHEMBL5363335 | 0.72 | ADORA1 (0.51) | ADORA1 | |
| SCHEMBL5357433 | 0.72 | ADORA1 (0.53) | ADORA1 | |
| SCHEMBL5359569 | 0.72 | ADORA1 (0.53) | ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202245-B2 | Substituted 4-amino[1,2,4]triazolo[4,3-a] quinoxalines | PFIZER INC. (US) | 2007-04-10 | — | — | US | claimed |
| EP-1613629-A1 | SUBSTITUTED 4-AMINO 1,2,4 TRIAZOLO 4,3-A QUINOXALINES | Pfizer Products Inc. (US) | 2006-01-11 | — | — | EP | claimed |
| WO-2004085439-A1 | SUBSTITUTED 4-AMINO[1,2,4]TRIAZOLO[4,3-A]QUINOXALINES | PFIZER PRODUCTS INC. (US) | 2004-10-07 | — | — | WO | claimed |
| US-20040192698-A1 | Substituted 4-amino[1,2,4]triazolo[4,3-a] quinoxalines | PFIZER INC. | 2004-09-30 | — | — | US | claimed |
| US-7202245-B2 | Substituted 4-amino[1,2,4]triazolo[4,3-a] quinoxalines | PFIZER INC. (US) | 2007-04-10 | — | — | US | disclosed |
| EP-1613629-A1 | SUBSTITUTED 4-AMINO 1,2,4 TRIAZOLO 4,3-A QUINOXALINES | Pfizer Products Inc. (US) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004085439-A1 | SUBSTITUTED 4-AMINO[1,2,4]TRIAZOLO[4,3-A]QUINOXALINES | PFIZER PRODUCTS INC. (US) | 2004-10-07 | — | — | WO | disclosed |
| US-20040192698-A1 | Substituted 4-amino[1,2,4]triazolo[4,3-a] quinoxalines | PFIZER INC. | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192698-A1 | Substituted 4-amino[1,2,4]triazolo[4,3-a] quinoxalines | CYP4B1, CYP3A4, CYP1B1 | ADORA1 12/4885ADORA3 26/4885ADORA2A 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.